Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)-Reference-Cited by-同舟云学术

Prognostic value of POD24 validation in follicular lymphoma patients initially treated with chemotherapy‐free regimens in a pooled analysis of three randomized trials of the Swiss Group for Clinical Cancer Research (SAKK)

Published:2020-08-17 Issue:6 Volume:192 Page:1031-1034
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Moccia Alden Alberto¹^ORCID,Schär Sämi²,Hayoz Stefanie²,Pirosa Maria Cristina¹,Taverna Christian³,Novak Urban⁴,Kimby Eva⁵^ORCID,Ghielmini Michele¹,Zucca Emanuele¹⁴⁶

Affiliation:

1. Clinic of Medical Oncology Oncology Institute of Southern Switzerland BellinzonaSwitzerland

2. SAKK Coordinating Center BernSwitzerland

3. Division of Medical Oncology Kantonsspital Münsterlingen MünsterlingenSwitzerland

4. Department of Medical Oncology Inselspita/Bern University Hospital Bern Switzerland

5. Unit of Hematology, Department of Medicine at Huddinge Karolinska Institutet Stockholm Sweden

6. Institute of Oncology Research Faculty of Biomedical Sciences Università della Svizzera italiana Bellinzona Switzerland

Funder

Celgene

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.17045

Reference10 articles.

1. Life expectancy of young adults with follicular lymphoma

2. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

3. Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma

4. Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy

5. Chemotherapy-Free Initial Treatment of Advanced Indolent Lymphoma Has Durable Effect With Low Toxicity: Results From Two Nordic Lymphoma Group Trials With More Than 10 Years of Follow-Up

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How Should We Risk Stratify and Tailor Therapy for Relapsed/Refractory Indolent Lymphoma?;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Current and future therapies for follicular lymphoma;Experimental Hematology & Oncology;2024-08-22

3. B-cell non-Hodgkin lymphomas;The Lancet;2024-05

4. Treatment sequencing and impact of number of treatment lines on survival in follicular lymphoma: A national population‐based study;eJHaem;2024-04-28

5. Gene expression and copy number profiling of follicular lymphoma biopsies from patients treated with first-line rituximab without chemotherapy;Leukemia & Lymphoma;2023-09-08